Intensive Motivational Interviewing for Methamphetamine Dependence
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01071356 |
Recruitment Status
:
Completed
First Posted
: February 19, 2010
Last Update Posted
: September 27, 2013
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Methamphetamine Dependence | Behavioral: Intensive Motivational Interviewing Behavioral: Single session of Motivational Interviewing | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 217 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Intensive Motivational Interviewing for Methamphetamine Dependence |
Study Start Date : | February 2009 |
Actual Primary Completion Date : | October 2012 |
Actual Study Completion Date : | October 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: 9 sessions of Motivational Interviewing
Respondents received 9 1-hour sessions of Motivational Interviewing therapy concurrent with outpatient drug treatment.
|
Behavioral: Intensive Motivational Interviewing
Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
|
Active Comparator: 1 session of Motivational Interviewing + 8 sessions nutrition
Respondents received one 1.5-hour session of Motivational Interviewing therapy at the outset of entering outpatient drug treatment.
|
Behavioral: Single session of Motivational Interviewing |
- Methamphetamine positive urine screens [ Time Frame: Weekly while in treatment (9 weeks) and 4 and 6 month follow up ]
- Addiction Severity Index [ Time Frame: Baseline, 2-,4-, and 6-month follow up ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 18 years old,
- Meets DSM IV criteria for MA dependence during the past year as assesses by the DSM-IV Checklist,
- able to speak and read English,
- capable of giving informed consent, and
- likely to be in the area the next 6 months.
Exclusion Criteria:
- requires inpatient treatment for detoxification, medical or psychiatric treatment, and
- Serious psychiatric condition that would impair their ability to provide informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01071356
United States, California | |
Alcohol Research Group | |
Emeryville, California, United States, 94608 |
Principal Investigator: | Douglas Polcin, Ed.D. | Alcohol Research Group / Public Health Institute |
Additional Information:
Responsible Party: | Alcoholresearchgroup, Douglas L Polcin, Ed.D, Public Health Institute, California |
ClinicalTrials.gov Identifier: | NCT01071356 History of Changes |
Other Study ID Numbers: |
1R01DA024714 ( U.S. NIH Grant/Contract ) |
First Posted: | February 19, 2010 Key Record Dates |
Last Update Posted: | September 27, 2013 |
Last Verified: | September 2013 |
Keywords provided by Alcoholresearchgroup, Public Health Institute, California:
methamphetamine motivational interviewing |
Additional relevant MeSH terms:
Methamphetamine Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Dopamine Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Dopamine Uptake Inhibitors |